Volume Overload in Heart Failure: An Evidence-Based Review of Strategies for Treatment and Prevention

Mayo Clinic Proceedings

Volumn 90, Issue 9, 2015, Pages 1247-1261

  Houston, Brian A ^a   Kalathiya, Rohan J ^a   Kim, Daniel A ^a   Zakaria, Sammy ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AZOSEMIDE; BUMETANIDE; CHLOROTHIAZIDE; CHLORTALIDONE; CONIVAPTAN; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; ELECTROLYTE; EPLERENONE; ETACRYNIC ACID; FUROSEMIDE; LIXIVAPTAN; LOOP DIURETIC AGENT; METOLAZONE; NESIRITIDE; PLACEBO; POTASSIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TORASEMIDE; VASOPRESSIN ANTAGONIST; CARDIOTONIC AGENT; NATRIURETIC FACTOR;

ACUTE HEART FAILURE; AMENORRHEA; BLEEDING DISORDER; BLOOD PRESSURE MONITORING; BOLUS INJECTION; COMPUTER PROGRAM; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROL STRATEGY; DIURETIC THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DYSMENORRHEA; DYSPNEA; EDEMA; ELECTROLYTE BLOOD LEVEL; ELECTROLYTE DISTURBANCE; ESSENTIAL HYPERTENSION; EVIDENCE BASED PRACTICE; FATIGUE; GUT EDEMA; GYNECOMASTIA; HEART FAILURE; HEART RHYTHM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERVOLEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; IMPEDANCE CARDIOGRAPHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTABLE HEMODYNAMIC MONITOR; INJECTION SITE PHLEBITIS; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MONOTHERAPY; OTOTOXICITY; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SODIUM RESTRICTION; SYSTOLIC HEART FAILURE; TELEMONITORING; TREATMENT RESPONSE; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT; URINE VOLUME; VITAL SIGN; ACUTE DISEASE; DISEASE COURSE; DISEASE MANAGEMENT; EPIDEMIOLOGY; UNITED STATES;

ACUTE DISEASE; CARDIOTONIC AGENTS; DISEASE MANAGEMENT; DISEASE PROGRESSION; HEART FAILURE; HUMANS; NATRIURETIC AGENTS; UNITED STATES;

EID: 84940613359     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.05.002     Document Type: Review

References (99)

1. P.A. Heidenreich, N.M. Albert, L.A. Allen, and et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association Circ Heart Failure 6 3 2013 606 619
2. M.E. Rea, and M.E. Dunlap Renal hemodynamics in heart failure: implications for treatment Curr Opin Nephrol Hypertens 17 1 2008 87 92
3. I.S. Anand, L.D. Fisher, and Y.T. Chiang Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT) Circulation 107 9 2003 1278 1283
4. B.D. Rose Diuretics Kidney Int 39 2 1991 336 352
5. B. Bikdeli, K.M. Strait, K. Dharmarajan, and et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J Am Coll Cardiol 61 14 2013 1549 1550
6. L.P. Rybak Ototoxicity of ethacrynic acid (a persistent clinical problem) J Laryngol Otol 102 6 1988 518 520
7. G.C. Wall, D. Bigner, and S. Craig Ethacrynic acid and the sulfa-sensitive patient Arch Intern Med 163 1 2003 116 117
8. D.L. Vargo, W.G. Kramer, P.K. Black, W.B. Smith, T. Serpas, and D.C. Brater Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure Clin Pharmacol Ther 57 6 1995 601 609
9. M.R. Vasco, D. Brown-Cartwright, J.P. Knochel, J.V. Nixon, and D.C. Brater Furosemide absorption altered in decompensated congestive heart failure Ann Intern Med 102 3 1985 314 318
10. G. Bailie, A. Grennan, and S. Waldek Bioavailability of bumetanide in grossly oedematous patients Clin Pharmacokinet 12 6 1987 440 443
11. B.E. Bleske, L.S. Welage, W.G. Kramer, and J.M. Nicklas Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure J Clin Pharmacol 38 8 1998 708 714
12. S. Kasama, T. Toyama, T. Hatori, and et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure Heart 92 10 2006 1434 1440
13. T. Uchida, K. Yamanaga, M. Nishikawa, Y. Ohtaki, H. Kido, and M. Watanabe Anti-aldosteronergic effect of torasemide Eur J Pharmacol 205 2 1991 145 150
14. J. Cosin, J. Diez TORIC Investigators Torasemide in chronic heart failure: results of the TORIC study Eur J Heart Fail 4 4 2002 507 513
15. N. Ferrara, D. Leosco, M. Del Prete, and et al. Torasemide versus furosemide in patients with congestive heart failure: a double-masked, randomized study Curr Ther Res 58 5 1997 291 299
16. B. Lopez, R. Querejeta, A. Gonzalez, E. Sanchez, M. Larman, and J. Diez Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure J Am Coll Cardiol 43 11 2004 2028 2035
17. M.D. Murray, M.M. Deer, J.A. Ferguson, and et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure Am J Med 111 7 2001 513 520
18. K. Muller, G. Gamba, F. Jaquet, and B. Hess Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV: efficacy and quality of life Eur J Heart Fail 5 6 2003 793 801
19. T. Masuyama, T. Tsujino, H. Origasa, and et al. Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure Circ J 76 4 2012 833 842
20. G.M. Felker, K.L. Lee, D.A. Bull, and et al. Diuretic strategies in patients with acute decompensated heart failure N Engl J Med 364 9 2011 797 805
21. P.A. James, S. Oparil, B.L. Carter, and et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 5 2014 507 520
22. D.H. Ellison The physiologic basis of diuretic synergism: its role in treating diuretic resistance Ann Intern Med 114 10 1991 886 894
23. G.H. Kim Long-term adaptation of renal ion transporters to chronic diuretic treatment Am J Nephrol 24 6 2004 595 605
24. D. Aravot, N. Banner, F. Musumeci, and et al. Oral metolazone plus furosemide for home therapy in patients with refractory heart failure Lancet 333 8640 1989 727 728
25. K.S. Channer, K.A. McLean, P. Lawson-Matthew, and M. Richardson Combination diuretic treatment in severe heart failure: a randomised controlled trial Br Heart J 71 2 1994 146 150
26. J.C. Jentzer, T.A. DeWald, and A.F. Hernandez Combination of loop diuretics with thiazide-type diuretics in heart failure J Am Coll Cardiol 56 19 2010 1527 1534
27. B. Pitt, W. Remme, F. Zannad, and et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 14 2003 1309 1321
28. B. Pitt, F. Zannad, W.J. Remme, and et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 10 1999 709 717
29. F. Zannad, J.J. McMurray, H. Krum, and et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 1 2011 11 21
30. J.E. Udelson, A.M. Feldman, B. Greenberg, and et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction Circ Heart Fail 3 3 2010 347 353
31. A.A. van Vliet, A.J. Donker, J.J. Nauta, and F.W. Verheugt Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor Am J Cardiol 71 3 1993 21A 28A
32. J.P. Ferreira, M. Santos, S. Almeida, I. Marques, P. Bettencourt, and H. Carvalho Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure Eur J Intern Med 25 1 2014 67 72
33. J. Rossi, M. Bayram, J. Udelson, and et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial Acute Card Care 9 2 2007 82 86
34. P.J. Hauptman, J. Burnett, M. Gheorghiade, and et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan J Card Fail 19 6 2013 390 397
35. W.T. Abraham, A.A. Shamshirsaz, K. McFann, R.M. Oren, and R.W. Schrier Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients J Am Coll Cardiol 47 8 2006 1615 1621
36. W.T. Abraham, J.M. Aranda, J.P. Boehmer, and et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study Clin Transl Sci 3 5 2010 249 253
37. S.R. Goldsmith, U. Elkayam, W.H. Haught, A. Barve, and W. He Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study J Card Fail 14 8 2008 641 647
38. R.M. Carey, H.M. Siragy, N.V. Ragsdale, and et al. Dopamine-1 and dopamine-2 mechanisms in the control of renal function Am J Hypertens 3 6 1990 59S 63S
39. T. Satoh, M. Ominato, and A.I. Katz Different mechanisms of renal Na-KATPase regulation by dopamine in the proximal and distal nephron Hypertens Res 18 suppl 1 1995 S137 S140
40. P.E. Marik Low-dose dopamine: a systematic review Intens Care Med 28 7 2002 877 883
41. J.A. Kellum, and J.M. Decker Use of dopamine in acute renal failure: a meta-analysis Crit Care Med 29 8 2001 1526 1531
42. J.O. Friedrich, N. Adhikari, M.S. Herridge, and J. Beyene Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death Ann Intern Med 142 7 2005 510 524
43. P. Varriale, and A. Mossavi The benefit of low-dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency: does it protect renal function? Clin Cardiol 20 7 1997 627 630
44. E.F. Aziz, C.L. Alviar, E. Herzog, and et al. Continuous infusion of furosemide combined with low-dose dopamine compared to intermittent boluses in acutely decompensated heart failure is less nephrotoxic and carries a lower readmission at thirty days Hellenic J Cardiol 52 3 2011 227 235
45. G. Giamouzis, J. Butler, R.C. Starling, and et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial J Card Fail 16 12 2010 922 930
46. H. Chen, K.J. Anstrom, M.M. Givertz, and et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial JAMA 310 23 2013 2533 2543
47. H.H. Chen, O.F. AbouEzzeddine, K.J. Anstrom, and et al. Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial Circ Heart Fail 6 5 2013 1087 1094
48. D.A. MacGregor, T.E. Smith, R.C. Prielipp, J.F. Butterworth, R.L. James, and P.E. Scuderi Pharmacokinetics of dopamine in healthy male subjects Anesthesiology 92 2 2000 338 346
49. A. Lauschke, U.K. Teichgräber, U. Frei, and K.U. Eckardt "Low-dose" dopamine worsens renal perfusion in patients with acute renal failure Kidney Int 69 9 2006 1669 1674
50. A. Ungar, S. Fumagalli, M. Marini, and et al. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure Crit Care Med 32 5 2004 1125 1129
51. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) Intravenous nesiritide vs nitroglycerin for treatment of decompensated heart failure: a randomized controlled trial JAMA 287 12 2002 1531 1540
52. W.S. Colucci, U. Elkayam, D.P. Horton, and et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure N Engl J Med 343 4 2000 246 253
53. A.J. Burger, D.P. Horton, T. LeJemtel, and et al. Effect of nesiritide (b-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study Am Heart J 144 6 2002 1102 1108
54. J.D. Sackner-Bernstein, H.A. Skopicki, and K. Aaronson Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure Circulation 111 12 2005 1487 1491
55. J.D. Sackner-Bernstein, M. Kowalski, M. Fox, and K. Aaronson Short-term risk of deathafter treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials JAMA 293 15 2005 1900 1905
56. C.W. Yancy, H. Krum, B.M. Massie, and et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial Circ Heart Fail 1 1 2008 9 16
57. C.M. O'Connor, R.C. Starling, A.F. Hernandez, and et al. effect of nesiritide in patients with acute decompensated heart failure N Engl J Med 365 1 2011 32 43
58. S.S. Gottlieb, A. Stebbins, A.A. Voors, and et al. Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure) J Am Coll Cardiol 62 13 2013 1177 1183
59. E.J. Topol The lost decade of nesiritide N Engl J Med 365 1 2011 81 82
60. T.G. Dahle, D. Blake, S.S. Ali, C.C. Olinger, M.C. Bunte, and A.J. Boyle Large volume ultrafiltration for acute decompensated heart failure using standard peripheral intravenous catheters J Card Fail 12 5 2006 349 352
61. B.A. Bart, A. Boyle, A.J. Bank, and et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial J Am Coll Cardiol 46 11 2005 2043 2046
62. B.E. Jaski, A. Romeo, B. Ortiz, and et al. Outcomes of volume-overloaded cardiovascular patients treated with ultrafiltration J Card Fail 14 6 2008 515 520
63. M.R. Costanzo, M. Saltzberg, J. O'Sullivan, and P. Sobotka Early ultrafiltration in patients with decompensated heart failure and diuretic resistance J Am Coll Cardiol 46 11 2005 2047 2051
64. P.G. Agostoni, G.C. Marenzi, M. Pepi, and et al. Isolated ultrafiltration in moderate congestive heart failure J Am Coll Cardiol 21 2 1993 424 431
65. P. Agostoni, G. Marenzi, G. Lauri, and et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result Am J Med 96 3 1994 191 199
66. M.R. Costanzo, M.E. Guglin, M.T. Saltzberg, et al. UNLOAD Trial Investigators Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 49 6 2007 675 683
67. H.L. Rogers, J. Marshall, J. Bock, and et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure J Card Fail 14 1 2008 1 5
68. B.A. Bart, S.R. Goldsmith, K.L. Lee, and et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome N Engl J Med 367 24 2012 2296 2304
69. ClinicalTrials.gov. Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment (AVOID-HF). https://clinicaltrials.gov/ct2/show/NCT01474200. Accessed May 23, 2015.
70. M. Volpe, C. Tritto, N. DeLuca, and et al. Abnormalities of sodium handling and of cardiovascular adaptations during high salt diet in patients with mild heart failure Circulation 88 4, pt 1 1993 1620 1627
71. M. Damgaard, P. Norsk, F. Gustafsson, and et al. Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure Am J Physiol Regul Integr Comp Physiol 290 5 2006 R1294 R1301
72. J.A. Borke, and P.C. Wyer Eating a larger number of high-salt foods is not associated with short-term risk of acute decompensation in patients with chronic heart failure J Emerg Med 44 1 2013 36 45
73. S.I. Chaudhry, Y. Wang, J. Concato, T.M. Gill, and H.M. Krumholz Patterns of weight change preceding hospitalization for heart failure Circulation 116 14 2007 1549 1554
74. M.R. Zile, T.D. Bennett, M. St John Sutton, and et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures Circulation 118 14 2008 1433 1441
75. S. Paterna, P. Gaspare, S. Fasullo, F.M. Sarullo, and P. Di Pasquale Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin Sci 114 3 2008 221 230
76. S. Paterna, G. Parrinello, S. Cannizzaro, and et al. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure Am J Cardiol 103 1 2009 93 102
77. J. Arcand, J. Ivanov, A. Sasson, and et al. A high-sodium diet is associated with acute decompensated heart failure in ambulatory heart failure patients: a prospective follow-up study Am J Clin Nutr 93 2 2011 332 337
78. G.B. Aliti, E.R. Rabelo, N. Clausell, L.E. Rohde, A. Biolo, and L. Beck-da-Silva Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial JAMA 173 12 2013 1058 1064
79. G. Licata, P. Di Pasquale, G. Parrinello, and et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects Am Heart J 145 3 2003 459 466
80. R.S. Taylor, K.E. Ashton, T. Moxham, L. Hooper, and S. Ebrahim Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review) Am J Hypertens 24 8 2011 843 853
81. C.W. Yancy, M. Jessup, B. Bozkurt, and et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 128 16 2013 e240 e327
82. J. Arcand, and G.E. Newton Dietary sodium reduction in heart failure: a challenge to the Cochrane Review Am J Hypertens 25 1 2012 19 author reply 20
83. Centers for Medicaid and Medicare Services. Readmissions Reduction Program. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.html. Last updated August 4, 2014. Accessed May 23, 2015.
84. L.R. Goldberg, J.D. Piette, M.N. Walsh, and et al. Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring in Heart Failure (WHARF) trial Am Heart J 146 4 2003 705 712
85. S.I. Chaudhry, J.A. Mattera, J.P. Curtis, and et al. Telemonitoring in patients with heart failure N Engl J Med 363 24 2010 2301 2309
86. F. Koehler, S. Winkler, M. Schieber, and et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study Circulation 123 17 2011 1873 1880
87. H.H. Woltjer, H.J. Bogaard, and P.M. de Vries The technique of impedance cardiography Eur Heart J 18 9 1997 1396 1403
88. M. Packer, W.T. Abraham, M.R. Mehra, and et al. Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure J Am Coll Cardiol 47 11 2006 2245 2252
89. ClinicalTrials.gov. report-HF: Prevention of Heart Failure Events With Impedance Cardiography Testing. https://clinicaltrials.gov/show/NCT00409916. Accessed May 23, 2015.
90. G.V. Sharma, P.A. Woods, C.T. Lambrew, and et al. Evaluation of a noninvasive system for determining left ventricular filling pressure Arch Intern Med 162 18 2002 2084 2088
91. G.V. Sharma, P.A. Woods, N. Lindsey, and et al. Noninvasive monitoring of left ventricular end-diastolic pressure reduces rehospitalization rates in patients hospitalized for heart failure: a randomized controlled trial J Card Fail 17 9 2011 718-712
92. R.C. Bourge, W.T. Abraham, P.B. Adamson, and et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study J Am Coll Cardiol 51 11 2008 1073 1079
93. P.B. Adamson, M.R. Gold, T. Bennett, and et al. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of the Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial Congest Heart Fail 17 5 2011 248 254
94. W.T. Abraham, S. Compton, G. Haas, and et al. Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST) Congest Heart Fail 17 2 2011 51 55
95. D.J. van Veldhuisen, F. Braunschweig, V. Conraads, and et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure Circulation 124 16 2011 1719 1726
96. W.T. Abraham, P.B. Adamson, R.C. Bourge, and et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial Lancet 377 9766 2011 658 666
97. ClinicalTrials.gov. Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy (LAPTOP-HF). http://clinicaltrials.gov/show/NCT01121107. Accessed May 23, 2015.
98. J. Ritzema, R. Troughton, I. Melton, and et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure Circulation 121 9 2010 1086 1095
99. ClinicalTrials.gov. Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal (PAPIRUS III). https://clinicaltrials.gov/show/NCT00893828. Accessed May 23, 2015.